Mon Sep 28 2020

The University Hospital of Salamanca recently chose suPARnostic® TurbiLatex for routine clinical use, marking it as the product’s latest customer in Spain. This decision, influenced by successful pilot testing and positive data from both international and other Spanish users, aligns with the hospital’s goal to enhance patient triage. Salamanca’s hospital, renowned for its affiliation with Spain’s oldest university and its prominence in clinical research, is the fourth Spanish institution to adopt suPARnostic® TurbiLatex this year. As a leading facility in Castilla y León with 900 beds and serving a population of around 300,000, it plans to use the product in its Emergency Department and for treating COVID-19 patients.

Jakob Knudsen, Chief Executive Officer of ViroGates, says: ”We’re thrilled to announce that the University Hospital in Salamanca, Spain, has transitioned from a pilot phase to officially incorporating our product, suPARnostic® TurbiLatex, into their clinical routines. This major decision comes after the hospital placed its first order today, highlighting their confidence in our product’s benefits. The primary use focuses on patient triage in the emergency department, a decision significantly influenced by the current influx of patients testing positive for Covid-19.

1000+

published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 4 products:

Quick Triage

A Point of Care Solution

TurbiLatex

For Automated Systems

ELISA Assay

Clinical and Research

suPARnostic POC+

POC+

Point-of-care finger prick

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates